Trials and Fibrillations with Dr John Mandrola

HRS 2022 Taking Cardiac Pacing From Boring to Super-Cool Ablation has hogged the electrophysiology spotlight recently, but three presentations at the 2022 Heart Rhythm Society meeting put cardiac pacing on the comeback trail.
Experts And Viewpoints, May 09, 2022
ACC 2022 Sodium Restriction in Heart Failure: Another Dogma Felled If you still think that strict sodium limits are worthwhile in patients with heart failure, the onus is on you to prove it. They have enough to deal with, writes John Mandrola, MD.
Experts And Viewpoints, April 06, 2022
ACC 2022 Percutaneous Left Atrial Appendage Occlusion: Promise vs Reality The selling point of percutaneous left atrial appendage occlusion is to prevent stroke while avoiding the bleeding risk of antithrombotics. The data paint a different picture, writes John Mandrola, MD.
Experts And Viewpoints, April 04, 2022
ACC 2022 Mavacamten in HCM: Reasons for Optimism and Caution The novel drug helped patients avoid septal reduction therapy in the short term and approval looks likely, but more details and longer-term safety data will be needed before broader use, writes John Mandrola, MD.
Experts And Viewpoints, April 02, 2022
ACC 2022 Mandrola Previews ACC 2022 Studies on sodium restriction, fractional flow reserve, and strategies to improve patient and clinician behavior intrigue, but the best part of ACC22 is that it's largely in-person, writes John Mandrola, MD.
Experts And Viewpoints, March 29, 2022
CardioMEMS Remote HF Monitoring: Resist the Spin and FOMO An expanded indication based on a dubious post hoc analysis of GUIDE-HF should not allow the CardioMEMS HF system to become the therapeutic fashion, writes John Mandrola, MD.
Experts And Viewpoints, March 18, 2022
Mandrola's Top 10 Cardiology Stories of 2021 Obesity drugs had a good year, the SGLT2 inhibitors stalled, and Entresto looks less impressive -- these are some of the takes from John Mandrola, MD, in his annual review of cardiology research.
Experts And Viewpoints, December 15, 2021
AHA 2021 PCI vs CABG for Left Main CAD: A Never-Ending Debate? Controversies surrounding the EXCEL trial left questions about the data on stents vs bypass surgery in left main CAD. John Mandrola, MD, reviews a new independent meta-analysis presented at the 2021 AHA.
Experts And Viewpoints, November 19, 2021
AHA 2021 Early Surgery in Asymptomatic AS Should Wait Another trial favoring early surgery in patients with asymptomatic aortic stenosis is still not enough to change practice, argues this cardiologist.
Experts And Viewpoints, November 15, 2021
AHA 2021 Questions Remain on Tricuspid Repair at Time of Mitral Surgery The Cardiothoracic Surgical Trials Network trial on repair of mild-to-moderate tricuspid regurgitation in patients undergoing mitral valve surgery leaves this cardiologist with more questions than answers.
Experts And Viewpoints, November 13, 2021
AHA 2021 Mandrola Previews the Virtual AHA 2021 Trials on aortic stenosis, atrial fibrillation, and a pragmatic use of EHRs are among the picks from this year's American Heart Association scientific sessions.
Experts And Viewpoints, November 09, 2021
The MI–Mortality Mismatch: When Lowering MI Doesn't Extend Life An analysis challenges the notion that cardiovascular therapies that lower myocardial infarction extend survival. John Mandrola, MD, sees lessons for clinicians, patients, and researchers.
Experts And Viewpoints, November 04, 2021
ESC 2021 Ablate-and-Pace Delivers a Huge Win for Those Sick With AF In terms of clinical practice, the APAF-CRT trial was the standout from ESC for this electrophysiologist.
Experts And Viewpoints, September 02, 2021
ESC 2021 Lessons on AF Screening From the LOOP Study Screening for AF with an implantable monitor was not associated with lower stroke or systemic embolism overall, but the AF threshold was low and usual care was excellent, notes John Mandrola, MD.
Experts And Viewpoints, August 30, 2021
ESC 2021 Incremental, Not Monumental, Win for Empagliflozin in HFpEF The modest effects compel clinicians to be selective in the use of this costly drug, but there will be subgroups of patients who may benefit more, says John Mandrola, MD.
Experts And Viewpoints, August 28, 2021
ESC 2021 Mandrola Previews ESC 2021 A potential breakthrough in HFpEF, loop monitoring, a novel ablation strategy, and the saddest trial are highlighted by John Mandrola, MD, in his preview of the 2021 European Society of Cardiology sessions.
Experts And Viewpoints, August 23, 2021
HRS 2021 The Three Big Stories From HRS 2021 Presentations on pulsed field ablation and left bundle branch pacing caught the eye of this electrophysiologist. However, being able to meet in person trumped all at the 2021 Heart Rhythm Society meeting.
Experts And Viewpoints, August 05, 2021
Lessons From the Save of Christian Eriksen's Life The Danish soccer star went from 'being gone' to resuscitated. His widely watched experience teaches many lessons about improving care for sudden cardiac death, a major public health problem.
Experts And Viewpoints, June 28, 2021
ACC 2021 Renal Denervation for Resistant Hypertension Is Not Back on Track The RADIANCE-HTN-TRIO presentation at the recent American College of Cardiology meeting has this cardiologist asking if mineralocorticoid inhibition might beat an invasive procedure for resistant hypertension.
Experts And Viewpoints, May 20, 2021
ACC 2021 PARADISE-MI Makes Me Question the Benefits of Sacubitril/Valsartan Sacubitril valsartan (Entresto), deemed 'the Big E' by some clinicians, has fallen short in 2 of 3 clinical trials. The latest, presented at the ACC 2021 scientific session, is PARADISE-MI.
Experts And Viewpoints, May 16, 2021

No Results